Genmab — Maj 2019
-
interesting to read the transcript from Halo https://seekingalpha.com/article/4261245-halozyme-therapeutics-inc-halo-ceo-helen-torley-q1-2019-results-earnings-call-transcript?part=single
(by the way she thinks Analysts project sales this year of $2.7 billion) -
Genmab er med i denne analyse: http://www.proinvestor.com/debat/76852
-
-
Horizon Pharma is now Horizon Therapeutics plc. lol. Anyway, Continue to Expect Mid-2019 U.S. Biologics License Application (BLA) Submission for Teprotumumab . ( Teprotumumab has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA. If approved, teprotumumab would be the first and only approved treatment for active TED.) http://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-reports-strong-first-quarter-2019
-
@ E L thank you. That is really good news.
-
New trial : Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE) - https://clinicaltrials.gov/ct2/show/NCT03942224
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind